Filing Overview
Registrant: Agrify Corporation, although the request metadata identifies RYTHM, Inc. The filing is a Form 8-K reporting an event dated March 22, 2021. Agrify is a Nevada corporation traded on Nasdaq under AGFY.
Business Context and Reporting Period
The filing reports the closing of the underwriters’ over-allotment option related to Agrify’s February 2021 public offering. It is not a periodic financial statement and does not provide operating results for a reporting period.
Key Financial and Capitalization Metrics
- The original offering consisted of 5,555,555 shares at $13.50 per share.
- On March 22, 2021, the underwriters purchased an additional 833,333 shares at $13.50 per share.
- Total shares sold in the offering increased to 6,388,888.
- Total net proceeds were approximately $80 million after underwriting discounts and estimated offering expenses.
- The additional shares were subject to a 7% underwriting commission.
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity balances, or other operating metrics.
Material Changes Versus the Prior Comparable Period
The material change is the completion of the over-allotment sale, which increased gross share issuance by 833,333 shares and brought total offering proceeds to approximately $80 million net. The filing does not present comparative operating or financial results.
Guidance, Outlook, Risks, and Unusual Items
- No financial guidance or operating outlook is provided.
- The principal unusual item is the exercise and closing of the underwriters’ over-allotment option.
- The proceeds are subject to the offering terms, including underwriting discounts, commissions, and estimated expenses; the filing does not state a specific use-of-proceeds allocation.
- The offering was conducted under the company’s effective Form S-1 registration statement.
Investor Verification Checklist
- Confirm the correct issuer, as the supplied metadata names RYTHM, Inc., while the filing names Agrify Corporation.
- Verify the approximately $80 million net proceeds against the final prospectus and subsequent balance-sheet disclosures.
- Assess the dilution from the issuance of 6,388,888 shares and any related changes in shares outstanding.
- Review subsequent filings for the use of proceeds, liquidity, operating performance, and any additional financing.